The following 16 speakers will speak or work as judges at the BioBay Investor Forum 2011. (See the Detailed Agenda.)
Speakers, Panelists and Judges:
Min Cui, PhD - Managing Director, Bay City Capital
Dr. Min Cui is Managing Director of Bay City Capital China Fund. He joined Bay City Capital in October 2006, and focuses on evaluating investment opportunities for the firm and leads its initiatives in China. Dr. Cui was most recently Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005. In these positions, he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of GenturaDx and China Biologic Products. His investment portfolio also includes Ion Torrent Systems, Epizyme and Sunesis. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America. He received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University.
Samantha Du, PhD - CEO, Hutchison Medipharma
Dr. Du is the CEO of Hutchison Medipharma Limited (HMPL) and Chief Scientific Officer of Hutchison Chi-Med, a London AIM listed company. Dr. Du joined Hutchison Whampoa in 2001 as the executive VP for healthcare investment and was one of the key founders of Hutchison Chi-Med. She played a key role in the successful IPO of Hutchison Chi-Med in London in May 2006. In 2002, Dr. Du founded and became the founding CEO of HMPL. Since the inception of the company, HMPL has been acclaimed as one of the leading biotech firms. Dr. Du received her Ph.D. in Biochemistry from the University of Cincinnati. Prior to Hutchison, she was in Pfizer’s global strategic operation division responsible for global licensing for metabolic diseases. She started her research career at Pfizer Connecticut and led teams that involved in multiple early and late stage product development in different therapeutic areas. Two of these programs have reached to the markets. She is currently an active advisor on healthcare and biotech issues for various government agencies and research institutions in China.
Charles Hsu, PhD, MBA - Venture Partner, Mustang Ventures
Dr. Hsu has over 26 years of life science industry experience, including 20 years as an investor and entrepreneur, focused on life science and healthcare ventures. Prior to joining Mustang in 2011, he was a Venture Partner with Bay City Capital, and prior to that, a general partner of the Walden Group and its affiliate Walden International. Prior to joining Walden, he co-managed life science investments at Advent International, a global private equity firm based in Boston. He has cofounded and invested in almost 30 companies, including Alpha Beta, AutoImmune, DNX, Axys Pharmaceuticals, KOSAN, Urocor, Lexicon Genetics, Telik, Biomatrix, RPI (later SiRNA) and Aviron, Inc., all of which went public on NASDAQ. He was a co-founding investor in RPI and Urocor. Aviron developed the Flumist nasal influenza vaccine which is now a basis for the global vaccine campaign against the H1N1 virus. Dr. Hsu is a frequently invited speaker and published author on various topics related to life sciences investing. He serves on the Board of the Jacobs University (Bremen, Germany) Foundation and is an advisor to the Chinese American Biopharmaceutical Society (CABS). He holds an AB (Magna Cum Laude) in Biochemistry from Harvard and his PhD (Genetics) and MBA degrees from Stanford.
James F. Ewing, JD, PhD - Partner, Foley & Lardner LLP
James F. Ewing is Vice Chair of Foley & Lardner’s Chemical, Biotechnology & Pharmaceutical Practice and a member of the Life Sciences, Food and Nanotechnology Industry Teams. Dr. Ewing primarily advises pharmaceutical, biotechnology, and nutraceutical clients. In the pharmaceutical and biotechnology sectors, Dr. Ewing works with companies engaged in drug discovery to develop and produce peptide and small molecule therapeutics, encompassing such technologies as computationally assisted drug design, immunology and vaccine technologies, stem cell technologies, neurobiology, drug delivery, gene therapy technologies, nanobiology technologies and biomedical devices.
Jennifer Hu, PhD - Director of Licensing & External Research, Merck & Co., Inc., USA
Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying, evaluating, and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc. in early 2008, Dr. Hu worked with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics since 2004. Prior to that, she worked at Affymetrix in various capacities, including as Program Manager of Toxicology/Pharmacogenomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program. Dr. Hu got her BS degree in Biochemistry from Peking University; PhD from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association – West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 17 years of research, management, & business development experience with US biotech and pharmaceutical industry.
William Hu, MBA - Partner, Qiming Venture Partners
Mr. William is a partner of Qiming Ventures, focusing on the investment in healthcare sector. He has over 12 years of investing, strategy consulting, and operating experience in healthcare sector. Prior to joining Qiming, he was the director with CITIC Future Investment, strategy consultant with IBM BCS, and product manager with Colorcon. William's investments on behalf of Qiming include Tigermed, Sangon Bioengineering, Coland Pharma, Arrail Dental, etc. William got bachelor of medicine from Shanghai Medical University and MBA from SIMBA (ENPC at Tongji Campus).
Linda Ji, JD - Vice Chair, China Practice, Foley & Lardner LLP
Linda Ji is vice chair of Foley & Lardner’s China Practice and is a member of the Transactional & Securities, Private Equity & Venture Capital, and International Practices, as well as the Emerging Technologies and Life Sciences Industry Teams. Ms. Ji's practice focuses on corporate and securities laws. Ms. Ji has advised both privately and publicly held companies (ranging from start-ups to Fortune 100 companies) in a variety of corporate transactional and securities matters, including company setup, private equity and venture capital financings, mergers and acquisitions, private placement of securities, IPOs and secondary public offerings of securities, as well as public company reporting and securities law compliance. Ms. Ji has broad experience in international business transactions, with emphasis on cross-U.S. and China transactions. Ms. Ji has also advised private equity and venture capital funds in connection with fund formation and investments in portfolio companies.
Liu Yuwen graduated from China Pharmaceutical University with an MS in Pharmaceutics and Master of Management at Fudan University, China and Norwegian Management School, and is a licensed pharmacist. She joined Capsugel®, a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to be QA manager in April 1998, then transferred to New Business Development department in 2000 to manage new product market opportunity exploration in great China region. In May 2003, she moved to Shanghai as Chief Representative to set up the representative office for Perrigo Company and to manage supply management and a Joint venture company. In December 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by Suzhou Industrial Park government, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech research and development. She became the general manager of BioBay, vice president of Suzhou Ventures Group, assistant director of Suzhou Industrial Park Science & Technology Bureau in August 2007. And in June 2010, she became the chairperson and CEO of BioBay.
Hongbo Lu, PhD, MBA - Executive Director, OrbiMed Asia
Dr. Hongbo Lu is an Executive Director at OrbiMed. Previously, Dr. Lu spent more than five years at Piper Jaffray & Co as an equity analyst. She led Piper’s China healthcare research team and was instrumental in building the firm’s brand in the Asian marketplace. Prior to her Wall Street career, Dr. Lu spent four years in life science start-up operations and business development at Zyomyx, Inc. Dr. Lu received a PhD in BioEngineering from the University of Washington, an MBA from the Haas School of Business at the University of California, Berkeley, and a BS/MS in Materials Science and Engineering from Tsinghua University in China.
Elton Satusky - Partner, Wilson Sonsini Goodrich & Rosati
Elton Satusky is a partner at Wilson Sonsini Goodrich & Rosati, where he has been advising companies on public and private securities offerings, mergers and acquisitions, and corporate governance since 2000. Elton’s primary focus is on the representation of the enterprise, and a large number of his clients are public and private venture-backed life science, medical technology, and biotechnology companies. He advises these clients throughout every aspect of their lifecycle, from start-up formation and multiple rounds of private venture financing and debt issuances, counseling management and boards of directors, and eventual liquidity. Elton has served as lead counsel in connection with numerous clients’ public offerings, including the IPOs of Endocyte, SenoRx, and XTENT, and has advised a wide array of companies in mergers and acquisitions, including the sale of clients to Boston Scientific, Bard, Guidant, Hansen Medical, AngioDynamics, Medtronic, Kyphon, and others. Elton received a bachelor of laws (LLB) in 1996 from Osgoode Hall Law School in Toronto and before attending law school completed two years of a Bachelor of Business Administration at York University.
Greg B. Scott - President and Founder, ChinaBio® LLC
Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded ChinaBio® LLC in January 2007 to identify and develop early stage life science companies in China and co-founded ChinaBio® Capital Partners, China’s only dedicated life science merchant bank, in 2010. ChinaBio has helped major U.S. and European companies identify and secure acquisitions, partners and novel technologies in China, and assisted early stage companies in raising over $400M in VC and government funding. ChinaBio has also organized over 20 events in China including ten Investor Forums and three Partnering Forums. Mr. Scott is also Executive Editor of ChinaBio® Today, the most widely read publication on China's life science industry, and president and co-founder of Life Science Angels, which has funded 38 biotechnology and medical device companies in the U.S. and China. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Mr. Scott lives and works in Shanghai but visits the U.S. several times a year to enjoy San Diego’s blue sky and sandy beaches.
Victor Shi, PhD - President, Asia Pacific, QIAGEN
Dr. Victor Shi is Asia Pacific President of QIAGEN, a publicly-listed world leading provider of sample and assay technologies in the field of molecular diagnostics. Dr. Shi heads QIAGEN’s commercial operations and strategic development in Asia and manages an organization with over 500 employees in 11 subsidiaries. Dr. Shi has over 17 years’ experience in life science business development, management and investment. Previously held positions include Managing Partner, Aura Partners (Shanghai and Hong Kong), Senior Vice President of Corporate Development, Bridge Pharmaceuticals (Menlo Park, California), Managing Director of Discovery Resources Group (Palo Alto, California), Vice President of Corporate Development at Genospectra (Fremont, California), and Director of Asia Operations at A. M. Pappas & Associates (Singapore). He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co. Dr. Shi holds PhD and MS degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China.
Jacky Wu - Deputy Director, Suzhou Industrial Park Science and Technology Development Center
Mr. Jacky Wu joined Suzhou Industrial Park Administrative Committee in 2002 in the Investment Promotion Bureau. Currently he serves as the deputy director of Suzhou Industrial Park Sci&Tech Development Center and the Senior Vice President of Suzhou Nanotech Co. Ltd and also the General Manager of Suzhou Industrial Park CHInano Investments Co. Ltd. He has been leading the SIP efforts in engaging Chinese domestic companies and overseas high-tech experts and companies to establish collaboration and presence in SIP. Mr. Wu graduated from Tsinghua University in 2000 with MS degree in Material Processing & automation and obtained his BS degree in Mechanical Engineering from Southeast University in China. He has one year study experience in NTU, Singapore in the Precision Engineering before joining SIPAC.
Stella Xu, PhD - Regional Head, Greater China & Southeast Asia, Roche Partnering
Dr. Stella Xu is the Regional Head of Greater China and Southeast Asia with Roche Partnering. Her major responsibilities include searching potential licensing opportunities (products/technologies) and supporting transaction discussions & alliance management in Asia. Prior to her current position, Stella had held multiple global positions in Roche Partnering in the US and led more than 30 product-focused due diligence projects and alliances, including the latest two major product licensing deals in Asia. Stella joined Roche from McKinsey & Company US, a premier management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey, she led consulting engagements with global biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella conducted biotech drug discovery work in oncology and inflammation. Stella received her PhD in Immunology and executive MBA training from Northwestern University, and her BS in Biophysics from Peking University.
Charles Yang, CPA, CFA, MBA - CEO, Tririver Capital Corporation
Mr. Yang is CEO and a founding partner of Tririver Capital, a leading investment bank boutique focusing on early-stage and growth-stage healthcare companies in China. Prior to founding Tririver, Mr. Yang was a Vice President of Merrill Lynch in New York City. Previously, Mr. Yang held various senior management positions at several chemical and healthcare firms in China. Mr. Yang is a CFA and a CPA (USA). He received his MBA from Thunderbird, the American Graduate School of International Management and his Bachelor degree in Econometrics from Nanjing University.
Guang Yang, PhD - Associate Director, Platform Technology, GlaxoSmithKline (China) R&D Co., Ltd.
Dr. Yang has nearly 15 years experience in the pharmaceutical industry. He specializes in small molecule drug target validation and assay technology development. He has successfully led multiple discovery programs from target selection to candidate compound identification and validation for various disease indications (eg. cancer, RA, asthma, metabolic syndrome, anti-infectious, etc.) in several global pharmaceutical companies from 1997 to 2008. Dr. Yang joined GSK R&D China in 2008 to facilitate the establishment of platform technology function in support of GSK’s local drug discovery efforts. Recently he expanded his role in GSK R&D China focusing on the development and commercialization of transformative drugs in China and the region.
Cecelia Zhou, MBA, CFA - Director of BD/M&A, Life Technologies
Ms. Cecelia Zhou is the Greater China Business Development, M&A and Integrations leader at Life Technologies. In her current role, she focuses on M&A opportunities as well as external partnerships and strategic alliances in the Greater China region. She is also the current Chief of Staff for the President of Greater China at Life Technologies, leading various strategic initiatives in the region. Prior to relocating to Shanghai last year, Ms. Zhou spent 5 years with Life Technologies in its San Diego headquarter, leading the M&A finance group of the Company. She has also held various other positions within Life Technologies including FP&A and Sales Operations. Prior to Life Technologies, Cecelia spent six years with Lehman Brothers working in various locations including Hong Kong, New York and Los Angeles. Her work experiences included investment banking, capital markets and equity research. Her clients included large financial institutions and sovereign banks in Asia Pacific, global conglomerates such as GE and Tyco, and high tech companies in the Silicon Valley. Cecelia holds an MBA from the Anderson School of Business at UCLA, and BA of Economics and East Asian Studies from Wesleyan University in Connecticut.
Copyright © 2017, ChinaBio® LLC - ChinaBio is a registered trademark of ChinaBio® LLC